Dermatology | New Developments | Pipeline Prospector

Applied Biology

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Applied Biology, in Collaboration With Brown University Researchers and Corpometria Institute

Lead Product(s): Dutasteride,Ivermectin,Azithromycin

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Brown University

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 24, 2020

Details:

Breakthrough Discovery By Applied Biology Scientists And Brown University Researchers Paves Way For A Generic Anti-Androgen As A Treatment For Covid-19

Sirona Biochem Corp

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Sirona Biochem Ships First Batch of TFC-1067 to Rodan + Fields

Lead Product(s): Difluorocyclohexyloxyphenol

Therapeutic Area: Dermatology Product Name: TFC-1067

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 16, 2020

Details:

Sirona has made its first shipment of compound, TFC-1067 to Rodan + Fields. Rodan + Fields will be the first to market for a consumer product utilizing TFC-1067 for the treatment of dyschromia.

Revance Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Revance and Mylan to Advance Development Program for Biosimilar to BOTOX®

Lead Product(s): OnabotulinumtoxinA

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Mylan Inc.

Deal Size: $100.0 million Upfront Cash: $25.0 million

Deal Type: Licensing Agreement June 01, 2020

Details:

Mylan has decided to move forward with a development plan, under a 351(k) pathway, for a proposed biosimilar to BOTOX® and BOTOX® Cosmetic (onabotulinumtoxinA), the market-leading neuromodulator.

Crescita Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Crescita Awarded Cannabis Research License from Health Canada

Lead Product(s): Cannabinoid based products

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 24, 2020

Details:

The cannabis research license by Health Canada allows the Crescita to possess cannabis for the purpose of research and development.

Sirona Biochem Corp

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Sirona Biochem: 100% Safety in Final Tox Study for Increased Concentration of TFC-1067

Lead Product(s): TFC-1067

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 22, 2020

Details:

TFC-1067 demonstrated very good skin compatibility and does not show a sensitizing effect.

WuXi Biologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Almirall and WuXi Biologics sign strategic collaboration agreement for multiple bispecific antibodies targeting dermatology diseases

Lead Product(s): Bispecific antibody

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Almirall

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 09, 2020

Details:

With this collaboration Almirall embarks on its strategy to develop highly innovative biologic products for dermatology diseases including atopic dermatitis.

23andMe

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Almirall signs a strategic agreement with 23andMe to license rights of a bispecific monoclonal antibody that blocks all three isoforms of IL...

Lead Product(s): Bispecific antibody

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Almirall

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 09, 2020

Details:

Almirall will secure the rights to develop and commercialize the antibody for worldwide use. This agreement will strengthen Almirall's early-stage research portfolio.

Find

Find Novel Dermatology Drugs in Clinical Development

Undisclosed

Product Type

Companies

Applied Biology

Applied Biology, in Collaboration With Brown University Researchers and Corpometria Institute

Sirona Biochem Corp

Sirona Biochem Ships First Batch of TFC-1067 to Rodan + Fields

Revance Therapeutics

Revance and Mylan to Advance Development Program for Biosimilar to BOTOX®

Crescita Therapeutics

Crescita Awarded Cannabis Research License from Health Canada

Sirona Biochem Corp

Sirona Biochem: 100% Safety in Final Tox Study for Increased Concentration of TFC-1067

WuXi Biologics

Almirall and WuXi Biologics sign strategic collaboration agreement for multiple bispecific antibodies targeting dermatology diseases

23andMe

Almirall signs a strategic agreement with 23andMe to license rights of a bispecific monoclonal antibody that blocks all three isoforms of IL...